MedPath

Prophylactic administation of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-containing regime

Not Applicable
Conditions
Neoplasms
Registration Number
KCT0002985
Lead Sponsor
Chonnam National University Hospital Hwasun Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
33
Inclusion Criteria

(1) Relapsed or refractory multiple myeloma who received pomalidomide and dexamethasone-containing regimen
(2) Absolute neutrophil count = 15,000/µL at screening
(3) Age = 19 years
(4) ECOG PS = 2
(5) Subjects must have signed an informed consent document indicating that they understand purpose
of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria

(1) Smoldering myeloma
(2) Primary or secondary plasma cell leukemia
(3) History of radiation therapy within 4 weeks prior to enrolment
(4) Patients who have hypersensitivity to pegfilgrastim
(5) Presence of abnormal result of baseline test
Platelet count < 50,000 cells/µL (50 x 109/L) (when patients do not received a blood transfusion)
Serum AST or ALT > 3 X normal range
(6) Renal failure with hemodialysis or peritoneal dialysis
(7) Presence of Uncontrolled severe infection
(8) Pregnant or lactating female

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the incidence of severe neutropenia;the incidence of febrile neutropenia
Secondary Outcome Measures
NameTimeMethod
Duration of severe neutropenia;Frequency and duration of administation;Adverse events associated with pegfilgratim;change of immune function
© Copyright 2025. All Rights Reserved by MedPath